Download
s00262-019-02475-w.pdf 1,92MB
WeightNameValue
1000 Titel
  • Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma
1000 Autor/in
  1. Wagener-Ryczek, Svenja |
  2. Schoemmel, Max |
  3. Kraemer, Max |
  4. Bruns, Christiane |
  5. Schroeder, Wolfgang |
  6. Zander, Thomas |
  7. Gebauer, Florian |
  8. Alakus, Hakan |
  9. Merkelbach-Bruse, Sabine |
  10. Buettner, Reinhard |
  11. Loeser, Heike |
  12. Thelen, Martin |
  13. Schlößer, Hans A. |
  14. Quaas, Alexander |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-01-20
1000 Erschienen in
1000 Quellenangabe
  • 69(4):523-533
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00262-019-02475-w |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113210/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • The outcome in esophageal adenocarcinoma (EAC) is still poor with only 20% of patients in Western populations surviving for more than 5 years. Almost nothing is known about the precise composition of immune cells and their gene expression profiles in primary resected EACs and also nothing compared to neoadjuvant treated EACs. This study analyzes and compares immune profiles of primary resected and neoadjuvant treated esophageal adenocarcinoma and unravels possible targets for immunotherapy. We analyzed 47 EAC in total considering a set of 30 primary treatment-naive EACs and 17 neoadjuvant pretreated (12 × CROSS, 5 × FLOT) using the Nanostring's panel-based gene expression platform including 770 genes being important in malignant tumors and their immune micromileu. Most of the significantly altered genes are involved in the regulation of immune responses, T-and B cell functions as well as antigen processing. Chemokine-receptor axes like the CXCL9, -10,-11/CXCR3- are prominent in esophageal adenocarcinoma with a fold change of up to 9.5 promoting cancer cell proliferation and metastasis. ARG1, as a regulator of T-cell fate is sixfold down-regulated in untreated primary esophageal tumors. The influence of the currently used neoadjuvant treatment revealed a down-regulation of nearly all important checkpoint markers and inflammatory related genes in the local microenvironment. We found a higher expression of checkpoint markers like LAG3, TIM3, CTLA4 and CD276 in comparison to PD-L1/PD-1 supporting clinical trials analyzing the efficacy of a combination of different checkpoint inhibitors in EACs. We found an up-regulation of CD38 or LILRB1 as examples of additional immune escape mechanism.
1000 Sacherschließung
lokal Gene Expression Regulation, Neoplastic [MeSH]
lokal Esophageal Neoplasms/genetics [MeSH]
lokal T-Lymphocytes/metabolism [MeSH]
lokal Immune profile
lokal Esophageal Neoplasms/immunology [MeSH]
lokal Nanostring
lokal Neoadjuvant Therapy [MeSH]
lokal Original Article
lokal B7 Antigens/genetics [MeSH]
lokal Male [MeSH]
lokal Adenocarcinoma/immunology [MeSH]
lokal Monitoring, Immunologic [MeSH]
lokal CTLA-4 Antigen/immunology [MeSH]
lokal Female [MeSH]
lokal Adenocarcinoma/therapy [MeSH]
lokal Esophageal Neoplasms/therapy [MeSH]
lokal B7 Antigens/immunology [MeSH]
lokal T-Lymphocytes/immunology [MeSH]
lokal Humans [MeSH]
lokal Chemoradiotherapy/methods [MeSH]
lokal Middle Aged [MeSH]
lokal Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH]
lokal CTLA-4 Antigen/genetics [MeSH]
lokal Esophagectomy/methods [MeSH]
lokal Adenocarcinoma/genetics [MeSH]
lokal Gene Expression Profiling/methods [MeSH]
lokal Esophageal adenocarcinoma
lokal RNA expression
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-2870-5606|https://frl.publisso.de/adhoc/uri/U2Nob2VtbWVsLCBNYXg=|https://frl.publisso.de/adhoc/uri/S3JhZW1lciwgTWF4|https://frl.publisso.de/adhoc/uri/QnJ1bnMsIENocmlzdGlhbmU=|https://frl.publisso.de/adhoc/uri/U2Nocm9lZGVyLCBXb2xmZ2FuZw==|https://frl.publisso.de/adhoc/uri/WmFuZGVyLCBUaG9tYXM=|https://frl.publisso.de/adhoc/uri/R2ViYXVlciwgRmxvcmlhbg==|https://frl.publisso.de/adhoc/uri/QWxha3VzLCBIYWthbg==|https://frl.publisso.de/adhoc/uri/TWVya2VsYmFjaC1CcnVzZSwgU2FiaW5l|https://frl.publisso.de/adhoc/uri/QnVldHRuZXIsIFJlaW5oYXJk|https://frl.publisso.de/adhoc/uri/TG9lc2VyLCBIZWlrZQ==|https://frl.publisso.de/adhoc/uri/VGhlbGVuLCBNYXJ0aW4=|https://frl.publisso.de/adhoc/uri/U2NobMO2w59lciwgSGFucyBBLg==|https://frl.publisso.de/adhoc/uri/UXVhYXMsIEFsZXhhbmRlcg==
1000 Hinweis
  • DeepGreen-ID: 527445ef2d764370977eddadf536752a ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6470314.rdf
1000 Erstellt am 2023-11-18T05:30:17.634+0100
1000 Erstellt von 322
1000 beschreibt frl:6470314
1000 Zuletzt bearbeitet Fri Dec 01 11:32:41 CET 2023
1000 Objekt bearb. Fri Dec 01 11:32:41 CET 2023
1000 Vgl. frl:6470314
1000 Oai Id
  1. oai:frl.publisso.de:frl:6470314 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source